[1]梁婉玲,周怀胜,马海智,等.地塞米松玻璃体内植入剂Ozurdex治疗视网膜静脉阻塞继发黄斑水肿的短期疗效[J].眼科新进展,2019,39(7):666-669.[doi:10.13389/j.cnki.rao.2019.0153]
　LIANG Wan-Ling,ZHOU Huai-Sheng,MA Hai-Zhi,et al.The short-term efficacy of Ozurdex for macular edema secondary to retinal vein occlusion[J].Recent Advances in Ophthalmology,2019,39(7):666-669.[doi:10.13389/j.cnki.rao.2019.0153]
点击复制

地塞米松玻璃体内植入剂Ozurdex治疗视网膜静脉阻塞继发黄斑水肿的短期疗效/HTML
分享到：

《眼科新进展》[ISSN:1003-5141/CN:41-1105/R]

卷:
39卷
期数:
2019年7期
页码:
666-669
栏目:
应用研究
出版日期:
2019-07-05

文章信息/Info

Title:
The short-term efficacy of Ozurdex for macular edema secondary to retinal vein occlusion
作者:
梁婉玲; 周怀胜; 马海智; 卢彦; 晏世刚
528000　广东省佛山市，佛山市第二人民医院眼科中心
Author(s):
LIANG Wan-Ling; ZHOU Huai-Sheng; MA Hai-Zhi; LU Yan; YAN Shi-Gang
Department of Ophthalmology，the Second People’s Hospital of Foshan，Foshan 528000，Guangdong Province，China
关键词:
地塞米松玻璃体内植入剂; 视网膜静脉阻塞; 黄斑水肿; 雷珠单抗
Keywords:
dexamethasone intravitreal implant; retinal vein occlusion; macular edema; ranibizumab
分类号:
R774
DOI:
10.13389/j.cnki.rao.2019.0153
文献标志码:
A
摘要:
目的　通过比较地塞米松玻璃体内植入剂Ozurdex与雷珠单抗治疗视网膜静脉阻塞继发黄斑水肿（macular edema secondary to retinal vein occlusion，RVO-ME）的情况，评估Ozurdex的短期临床疗效。方法　回顾性分析2018年1月至12月就诊于佛山市第二人民医院眼科中心的RVO-ME患者（42例42眼）的临床资料。将其分为DEX组（11例）和抗VEGF组（31例）。观察两组患者治疗前后的最佳矫正视力（best corrected visual acuity，BCVA）、中央视网膜厚度（central retinal thickness，CRT）、药效持续时间（复发率）、不良反应等。结果　DEX组治疗后1个月、2个月、3个月和4个月的BCVA与治疗前比较差异均有统计学意义（均为P<0.05），治疗后6个月与治疗前比较差异无统计学意义（P=0.054）；DEX组治疗后1个月、2个月、3个月、4个月和6个月CRT与治疗前比较差异均有统计学意义（均为P<0.05）。抗VEGF组治疗后1个月BCVA、CRT与治疗前比较差异均有统计学意义（均为P<0.05）。治疗后1个月，DEX组与抗VEGF组间BCVA、CRT比较差异均无统计学意义（均为P>0.05）。DEX组内、抗VEGF组内及两者间视网膜分支静脉阻塞与视网膜中央静脉阻塞的BCVA、CRT比较除DXE组治疗后1个月CRT外，差异均无统计学意义（均为P>0.05）。DEX组的药效持续时间为3~4个月，抗VEGF组的药效持续时间<2个月。DEX组的高眼压发生率较抗VEGF组高，差异有统计学意义（P=0.004）。结论　Ozurdex在治疗RVO-ME上有明显的短期疗效，维持时间为3~4个月（少于6个月）。眼压仍是其需密切监控的主要不良反应。
Abstract:
Objective　To evaluate the short-term clinical efficacy of Ozurdex by comparing intravitreal injection of Ozurdex with ranibizumab in the treatment of macular edema secondary to retinal vein occlusion (RVO-ME).Methods　The clinical data of forty-two eyes of 42 RVO-ME patients who were admitted to the Department of Ophthalmology of the Second People’s Hospital of Foshan City from January to December 2018 were retrospectively analyzed.They were divided into two groups:DEX group with 11 patients and anti-VEGF group with 31 patients.The best corrected visual acuity(BCVA),central retinal thickness (CRT),duration of drug efficacy (recurrence rate),and adverse reactions of the two groups were observed before and after treatment.Results　The differences of BCVA at 1 month,2 months,3 months and 4 months after treatment in the DEX group were statistically significant than that before treatment (all P<0.05),while there was no statistical significance at 6 months after treatment (P=0.054).There were significant differences of CRT at 1 month,2 months,3 months,4 months and 6 months after treatment in the DEX group than that before treatment(all P<0.05).There were significant differences of BCVA and CRT in the anti-VEGF group at 1 month after treatment than those before treatment (both P<0.05).At 1 month after treatment,there were no significant differences of BCVA and CRT between the DEX group and the anti-VEGF group (both P>0.05).There were no significant differences between branch retinal vein occlusion and central retinal vein occlusion in the DEX group,the anti-VEGF group and between the two groups (all P>0.05),except for the CRT at 1 month after treatment in the DEX group.The duration of efficacy in the DEX group was 3 to 4 months,and the duration of efficacy in the anti-VEGF group was <2 months.The incidence of high intraocular pressure in the DEX group was higher than that in the anti-VEGF group,and the difference was statistically significant(P=0.004).Conclusion　Ozurdex has a significant short-term efficacy in the treatment of RVO-ME for a period of 3 to 4 months (less than 6 months).Intraocular pressure is still the main adverse reaction that needs to be closely monitored.

参考文献/References:

［1］　ROGERS S，MCINTOSH R L，CHEUNG N，LIM L，WANG J J，MITCHELL P，et al.The prevalence of retinal vein occlusion：pooled data from population studies from the United States，Europe，Asia，and Australia［J］.Ophthalmology，2010，117（2）：313-319.
［2］　THAPA R，BAJIMAYA S，PAUDYAL G，KHANAL S，TAN S，THAPA S S，et al.Prevalence，pattern and risk factors of retinal vein occlusion in an elderly population in Nepal：the Bhaktapur retina study［J］.BMC Ophthalmol，2017，17（1）：162.
［3］　STANCA H T，MANEA G.Physiopathology of macular edema in central vein occlusion［J］.Oftalmologia，2012，56（2）：15-20.
［4］　REHAK M，WIEDEMANN P.Retinal vein thrombosis：pathogenesis and management［J］.J Thromb Haemost，2010，8（9）：1886-1894.
［5］　CHEN S D，SUNDARAM V，LOCHHEAD J，PATEL C K.Intravitreal triamcinolone for the treatment of ischemic macular edema associated with branch retinal vein occlusion［J］.Am J Ophthalmol，2006，141（5）：876-883.
［6］　HUANG P，NIU W，NI Z，WANG R，SUN X.A meta-analysis of anti-vascular endothelial growth factor remedy for macular edema secondary to central retinal vein occlusion［J］.PLoS One，2013，8（12）：e82454.
［7］　BRAITHWAITE T，NANJI A A，GREENBERG P B.Anti-vascular endothelial growth factor for macular edema secondary to central retinal vein occlusion［J］.Cochrane Database Syst Rev，2010，10：CD007325.
［8］　LONDON N J，CHIANG A，HALLER J A.The dexamethasone drug delivery system：indications and evidence［J］.Adv Ther，2011，28（5）：351-366.
［9］　Evaluation of grid pattern photocoagulation for macular edema in central vein occlusion.The Central Vein Occlusion Study Group M Report［J］.Ophthalmology，1995，102（10）：1425-1433.
［10］　PATZ A.Argon laser photocoagulation for macular edema in branch vein occlusion［J］.Am J Ophthalmol，1984，98（3）：374-375.
［11］　PIELEN A，FELTGEN N，ISSERSTEDT C，CALLIZO J，JUNKER B，SCHMUCKER C.Efficacy and safety of intravitreal therapy in macular edema due to branch and central retinal vein occlusion：a systematic review［J］.PLoS One，2013，8（10）：e78538.
［12］　CHIQUET C，DUPUY C，BRON A M，APTEL F，STRAUB M，ISAICO R，et al.Intravitreal dexamethasone implant versus anti-VEGF injection for treatment-naive patients with retinal vein occlusion and macular edema：a 12-month follow-up study［J］.Graefes Arch Clin Exp Ophthalmol，2015，253（12）：2095-2102.
［13］　POMMIER S，MEYER F，GUIGOU S，BARTHELEMY T，GOBERT F，HAJJAR C，et al.Long-term real-life efficacy and safety of repeated Ozurdex? injections and factors associated with macular edema resolution after retinal vein occlusion：The REMIDO 2 Study［J］.Ophthalmologica，2016，236（4）：186-192.
［14］　LIN C J，CHEN H S，SU C W，TIEN P T，LIN J M，CHEN W L，et al.The effect of age and initial central retinal thickness on earlier need of repeat Ozurdex? treatment for macular edema due to retinal vein occlusion：a retrospective case series［J］.J Ocul Pharmacol Ther，2017，33（10）：763-772.
［15］　KARAGIANNIS D A，KARAMPELAS M D，SOUMPLIS V M，AMARIOTAKIS C，GEORGALAS I，KANDARAKIS A.Recurrence of macular edema in retinal vein occlusions after treatment with intravitreal ranibizumab （Lucentis）［J］.Can J Ophthalmol，2011，46（6）：486-490.
［16］　HALLER J A，BANDELLO F，BELFORT R，BLUMENKRANZ M S，GILLIES M，HEIER J，et al.Randomized，sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion［J］.Ophthalmology，2010，117（6）：1134-1146.
［17］　COSCAS G，AUGUSTIN A，BANDELLO F，DE SMET M D，LANZETTA P，STAURENGHI G，et al.Retreatment with Ozurdex for macular edema secondary to retinal vein occlusion［J］.Eur J Ophthalmol，2014，24（1）：1-9.
［18］　CHANG-LIN J E，ATTAR M，ACHEAMPONG A A，ROBINSON M R，WHITCUP S M，KUPPERMANN B D，et al.Pharmacokinetics and pharmacodynamics of a sustained-release dexamethasone intravitreal implant［J］.Invest Ophthalmol Vis Sci，2011，52（1）：80-86.
［19］　QUERQUES L，QUERQUES G，LATTANZIO R，GIGANTE S R，DEL TURCO C，CORRADETTI G，et al.Repeated intravitreal dexamethasone implant （Ozurdex（R）） for retinal vein occlusion［J］.Ophthalmologica，2013，229（1）：21-25.
［20］　PARRAVANO M，ODDONE F，BOCCASSINI B，GIORNO P，CHIARAVALLOTI A，TEDESCHI M，et al.Exploring the morphological and functional retinal changes after dexamethasone intravitreal implant （Ozurdex（R）） in macular edema due to retinal vein occlusion［J］.Ophthalmic Res，2014，51（3）：153-160.
［21］　TSERVAKIS I，KOUTSANDREA C，PAPACONSTANTINOU D，PARASKEVOPOULOS T，GEORGALAS I.Safety and efficacy of dexamethasone intravitreal implant （Ozurdex） for the treatment of persistent macular edema secondary to retinal vein occlusion in eyes previously treated with anti-vascular endothelial growth factors［J］.Curr Drug Saf，2015，10（2）：145-151.
［22］　OZKAYA A，TARAKCIOGLU H N，TANIR I.Ranibizumab versus dexamethasone implant in macular edema secondary to branch retinal vein occlusion：Two-year outcomes［J］.Optom Vis Sci，2018，95（12）：1149-1154.

相似文献/References:

[1]王刚.曲安奈德联合氪激光治疗视网膜静脉阻塞的临床疗效观察[J].眼科新进展,2013,33(7):000.
[2]马宇 刘意 郭娟 周利晓.金纳多联合血栓通对视网膜静脉阻塞患者同型半胱氨酸水平的影响[J].眼科新进展,2013,33(9):000.
[3]袁子茗 王帅 宋蓓雯 胡健艳 吴强.维速达尔光动力疗法诱导兔视网膜静脉阻塞的实验研究[J].眼科新进展,2012,32(9):000.
[4]李娟娟 李燕.先天性及获得性视盘血管袢的临床观察[J].眼科新进展,2013,33(11):000.
[5]陆秉文 吴星伟.视网膜静脉阻塞黄斑水肿患者玻璃体内注射ranibi-zumab后视野变化[J].眼科新进展,2013,33(12):000.
[6]金昱,石安娜,刘淼. 玻璃体内注射雷珠单抗（Ranibizumab）治疗视网膜静脉阻塞继发黄斑水肿[J].眼科新进展,2014,34(9):855.[doi:10.13389/j.cnki.rao.2014.0236]
[7]周洁,王宏彬,王文亭.雷珠单抗治疗视网膜静脉阻塞的临床研究[J].眼科新进展,2016,36(1):070.[doi:10.13389/j.cnki.rao.2016.0020]
　ZHOU Jie,WANG Hong-Bin,WANG Wen-Ting.Efficacy of intravitreal injection of ranibizumab for retinal vein occlusion[J].Recent Advances in Ophthalmology,2016,36(7):070.[doi:10.13389/j.cnki.rao.2016.0020]
[8]袁牧之,林颖,刘泉.视网膜静脉阻塞患者血浆和泪液中血管内皮生长因子表达的研究[J].眼科新进展,2016,36(5):468.[doi:10.13389/j.cnki.rao.2016.0125]
　YUAN Mu-Zhi,LIN Ying,LIU Quan.Expression of VEGF in plasma and tears of patients with RVO[J].Recent Advances in Ophthalmology,2016,36(7):468.[doi:10.13389/j.cnki.rao.2016.0125]
[9]王琛,李东豪,闻毅颐.玻璃体内注射康柏西普联合周边视网膜选择性光凝治疗视网膜静脉阻塞继发黄斑水肿的疗效及安全性[J].眼科新进展,2016,36(5):471.[doi:10.13389/j.cnki.rao.2016.0126]
　WANG Chen,LI Dong-Hao,WEN Yi-Yi.Intravitreal injection of conbercept combined with selective peripheral retinal photocoagulation for macular edema secondary to retinal vein occlusion[J].Recent Advances in Ophthalmology,2016,36(7):471.[doi:10.13389/j.cnki.rao.2016.0126]
[10]张敏,朱健华,冯浩,等.视网膜静脉阻塞合并黄斑水肿患者黄斑区微结构改变与视力的相关性分析[J].眼科新进展,2016,36(11):1061.[doi:10.13389/j.cnki.rao.2016.0283]
　ZHANG Min,ZHU Jian-Hua,FENG Hao,et al.Macular microstructure changes in retinal vein occlusion and its correlation with visual acuity[J].Recent Advances in Ophthalmology,2016,36(7):1061.[doi:10.13389/j.cnki.rao.2016.0283]

备注/Memo

备注/Memo:
广东省佛山市十三五医学重点专科和特色专科建设项目（编号：FSGSPZD135020）
更新日期/Last Update: 2019-07-01